Skip to main content
. 2013 Jan 25;8(1):e54472. doi: 10.1371/journal.pone.0054472

Figure 4. FXR agonism protects against colitis development in MyD88−/− mice.

Figure 4

TNBS colitis was induced in MyD88+/+ and MyD88−/− mice. Mice were administered 6-ECDCA, a FXR agonist, as described in materials and methods section. (A–C) Analysis of Disease activity index (DAI) in MyD88+/+ (A) and MyD88−/− mice (C). (B–D) Analysis of mucosal damage score in MyD88+/+ (B) and MyD88−/− mice (D). (E–L) H&E staining of representative paraffin-embedded sections from distal colons after administration of vehicle (control mice), TNBS or TNBS plus 6-ECDCA in MyD88+/+ (panels E–G) and MyD88−/− (H–L) mice. Data are mean ± SE of 6 animals.*P<0.05 versus wild type naive mice. #P<0.05 versus wild type mice administered TNBS.